The Prognostic Importance of Changes in CD4^+Cell Count and HIV-1 RNA Level in Women after Initiating Highly Active Antiretroviral Therapy

2004 ◽  
Vol 140 (4) ◽  
pp. 256 ◽  
Author(s):  
Kathryn Anastos
AIDS ◽  
2004 ◽  
Vol 18 (1) ◽  
pp. 45-49 ◽  
Author(s):  
Jean-Paul Viard ◽  
Marianne Burgard ◽  
Jean-Baptiste Hubert ◽  
Laurent Aaron ◽  
Cécile Rabian ◽  
...  

The Lancet ◽  
1998 ◽  
Vol 351 (9104) ◽  
pp. 723-724 ◽  
Author(s):  
Daniel Kaufmann ◽  
Giuseppe Pantaleo ◽  
Philippe Sudre ◽  
Amalio Telenti

AIDS ◽  
2001 ◽  
Vol 15 (17) ◽  
pp. 2325-2327 ◽  
Author(s):  
Andrea Antinori ◽  
Giuseppina Liuzzi ◽  
Antonella Cingolani ◽  
Ada Bertoli ◽  
Simona Di Giambenedetto ◽  
...  

2005 ◽  
Vol 16 (3) ◽  
pp. 243-246 ◽  
Author(s):  
Somnuek Sungkanuparph ◽  
Sasisopin Kiertiburanakul ◽  
Weerawat Manosuthi ◽  
Wiphawee Kiatatchasai ◽  
Asda Vibhagool

In developing countries, patients often present late with advanced AIDS and a very low CD4 cell count. A retrospective cohort study was conducted in HIV-infected patients who had been initiated into highly active antiretroviral therapy (HAART) with CD4 cell count <50 cells/mm3. There were 159 patients of mean age 36.6 years and 60.4% had previous major opportunistic infections. Mean CD4 was 22 cells/mm3 and 80% had HIV RNA>100,000 copies/mL. The majority of HAART regimens is non-nucleoside reverse transcriptase inhibitor-based (81.8%). In as-treated analysis, 50, 71.2, 79.7, 79.4, and 80.1% of patients achieved undetectable HIV RNA (<50 copies/mL) at 12, 24, 36, 48, and 60 weeks, respectively. The corresponding mean CD4 counts were 95, 125, 166, 201, and 225 cells/mm3. Twenty two patients (13.8%) had adverse drug events and half of these had to discontinue HAART. Initiation of HAART in advanced AIDS with CD4 cell count <50 cells/mm3 is effective, safe, and well tolerated and should not be delayed.


Sign in / Sign up

Export Citation Format

Share Document